News & Media
Media Contact:
David Hurley
CEO, Mandara Biopharma
News Releases
Mandara Biopharma Receives FDA Approval to Launch Their Clinical Trials for Alzheimer’s Agitation
BOULDER, Colo., February 17, 2026 – Mandara Biopharma Inc., a privately held U.S.-based biopharmaceutical company focused on novel therapies for central nervous system (CNS) disorders, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate their clinical trials for...
Mandara Biopharma Files IND with the FDA to Advance Dronabinol Oral Solution Formulation for Alzheimer’s Agitation
BOULDER, Colo., January 12, 2026 – Mandara Biopharma Inc., a privately held U.S.-based biopharmaceutical company focused on novel therapies for central nervous system (CNS) disorders, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to...